Space manufacturing sets the stage for next-gen therapies

The zero-gravity environment of orbit is emerging as a new frontier for biopharmaceutical innovation. According to GlobalData, microgravity allows biological and chemical processes to unfold in ways that cannot be replicated on Earth, offering drug developers a unique setting to advance disease modelling and therapeutic design.

Experiments aboard the International Space Station (ISS) have shown that protein crystals grown in space are more uniform and stable, potentially improving the precision of drug formulations. The insight could enable therapies that are more targeted and easier to deliver. Gaffar Aga, strategic intelligence analyst at GlobalData, said that microgravity provides “a novel insight into how biology truly operates,” while colleague George El-Helou described space as “a laboratory for innovation.”

Researchers are now using the environment to accelerate discoveries in 3D bio-printing and regenerative medicine. Human tissues printed in orbit have shown structures that cannot be formed under gravity, opening the possibility of organ printing for transplantation. In parallel, microgravity accelerates the aging of cells and tissues, giving scientists a faster route to study degenerative diseases and test anti-ageing treatments.